Please Note: Blog posts are not selected, edited or screened by Seeking Alpha editors.

Verenium Corp. (VRNM) And Novus Unveil New Phytase Enzyme Product, Unlocking The Hidden Value Of Phytate

Industrial biotechnology company Verenium and global animal health and nutrition solutions leader Novus International have announced the name of their new phytase enyme product.

Known as CIBENZA PHYTAVERSE, this new, innovative phytase is designed specifically to unlock more of the hidden nutritional value in phytate to improve animal growth and wellbeing.

Vernium and Novus, who entered into a strategic partnership in 2011, have designed CIBENZA PHYTAVERSE to have specific performance characteristics, offering significant advantages over current phytase products. The product's performance characteristics include: high in vivo activity under gastric conditions for sustained performance; improved activity at low substrate concentrations to maximize phytate hydrolysis; high gastric stability for activity throughout the upper gastrointestinal tract; high intrinsic thermotolerance and pelleting stability; and improved bioavailability due to eliminating the need for thermo protective coatings.

CIBENZA PHYTAVERSE has demonstrated these superior performance characteristics in animal trials, based on standard metrics like weight gain, feed conversion ratios, and phosphorous mineralization (tibia ash) as compared with other phytase products. The results have indicated that including CIBENZA PHYTAVERSE in monogastric diets can offer improved nutrition and economics to the animal feed industry.

The two companies plan to launch CIBENZA PHYTAVERSE in certain geographical regions beginning this year.

For more information, visit or

Please see disclaimer on the MissionIR website